Peptide analogues as a strategy to induce tolerance in T cells with indirect allospecificity

Transplantation

Volumn 70, Issue 4, 2000, Pages 631-640

  Frasca, Loredana ^a   Tamir, Ayala ^b   Jurcevic, Stipo ^c   Marinari, Barbara ^a   Monizio, Andrea ^a   Sorrentino, Rosa ^a   Carbonari, Maurizio ^a   Piccolella, Enza ^a   Lechler, Robert I ^b   Lombardi, Giovanna ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A2 ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 2; PEPTIDE DERIVATIVE; REAGENT;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIGEN BINDING; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; GRAFT REJECTION; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE CLONE; LYMPHOCYTE PROLIFERATION; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 0034721315     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200008270-00017     Document Type: Article

References (80)

1. Restoration of immunogenicity to passenger cell-depleted kidney allografts by addition of donor strain dendritic cells
2. High determinant density may explain the phenomenon of alloreactivity
3. Analysis of the alloreactive T cell repertoire in man
4. Hypothesis: Why do so many lymphocytes respond to major histocompatibility antigens?
5. Demonstration and characterization of Iapositive dendritic cells in the interstitial connective tissues of rat heart and other tissues, but not brain
6. Interstitial dendritic cells
7. Antigen presentation by keratinocytes induces tolerance in human T cells
8. Renal allograft rejection
9. Major histocompatibility complex class II-expressing endothelial cells induce allospecific nonresponsiveness in naive T cells
10. Antigen presentation by epithelial cells induces anergic immunoregulatory CD45RO+ T cells and deletion of CD45RA+ T cells
11. Antigen presentation by interferon-γ-treated thyroid follicular cells inhibits interleukin-2 (IL-2) and supports IL-4 production by B7-dependent human T cells
12. Interferon-γ-treated renal tubular epithelial cells induce allospecific tolerance
13. Detection of donor-specific hyporesponsiveness following late failure of human renal allograft
14. T cells sensitized to synthetic HLA-DR3 peptide give evidence of continuous presentation of denatured HLA-DR3 molecules by HLA-DP
15. Donor major histocompatibility complex (MHC) peptides are presented by recipient MHC molecules during graft rejection
16. Rejection of skin allografts by indirect allorecognition of donor class I major histocompatibility complex peptides
17. Contribution of direct and indirect recognition pathways to T cells alloreactivity
18. Indirect recognition of donor HLA-DR peptides in organ allograft rejection
19. Antigen processing and presentation in transplantation
20. Indirect T-cell allorecognition: Perspectives for peptide-based therapy in transplantation
21. Persistent allopeptide reactivity and epitope spreading in chronic rejection of organ allografts
22. The role of 'indirect' recognition in initiating rejection of skin grains from major histocompatibility complex class II-deficient mice
23. Indirect recognition by helper cells can induce donor-specific cytotoxic T lymphocytes in vivo
24. Cellular and humoral mechanisms of vascularized allograft rejection induced by indirect recognition of donor MHC allopeptides
25. Persistent allopeptide reactivity and epitope spreading in chronic rejection of organ allografts
26. Role of donor and recipient antigen-presenting cells in priming and maintaining T cells with indirect allospecificity
27. T cell unresponsiveness in vivo and in vitro: Fine specificity of induction and molecular characterization of the unresponsive state
28. B7 but not intracellular adhesion molecule-1 costimulation prevents the induction of human alloantigen specific tolerance
29. Invitro induction of T cell anergy by blocking B7 and early T cell costimulatory molecule ETC/B7
30. Blockade of the CD28 co-stimulatory pathway: A means to induce tolerance
31. Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells
32. Th2 cell clonal anergy as a consequence of partial activation
33. Induction of anergy in human T helper 0 cells by stimulation with altered T cell antigen receptor ligands
34. Persistence of peptide-induced CD4+ T cell anergy in vitro
35. Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand
36. Peptide analogs with different affinities for MHC alter the cytokine profile of T helper cells
37. Heteroclitic proliferative responses and changes in cytokine profile induced by altered peptides: Implications for autoimmunity
38. Variant antigenic peptide promotes cytotoxic T lymphocyte adhesion to target cells without cytotoxicity
39. Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein
40. Antigen analog-major histocompatibility complexes act as antagonists of the T cells receptor
41. Antagonism of superantigen-stimulated helper T-cell clones and hybridomas by altered peptide ligand
42. Antigen analogs/MHC complexes as specific T cell receptor antagonists
43. Inhibition of TCR triggering by a spectrum of altered peptide ligands suggests the mechanism for TCR antagonism
44. Hypervariable region 1 variants act as TCR antagonists for HCV-specific CD4+ T cells
45. New approaches to specific immunomodulation in transplantation
46. A single amino acid change in a myelin basic protein peptide confers the capacity to prevent rather than induce experimental autoimmune encephalomyelitis
47. T cell receptor antagonist peptides are highly effective inhibitors of experimental allergic encephalomyelitis
48. A single TCR antagonist peptide inhibits experimental allergic encephalomyelitis mediated by a diverse T cell repertoire
49. Inhibition of experimental autoimmune myasthenia gravis by major histocompatibility complex class II competitor peptides results not only in a suppressed but also in an altered immune response
50. A T cell receptor antagonist peptide induces T cells that mediate bystander suppression and prevent autoimmune encephalomyelitis induced with multiple myelin antigens
51. Altered peptide ligands act as partial agonists by inhibiting phospholipase C activity induced by myasthenogenetic T cell epitopes
52. In vitro peptide binding to soluble empty class I major histocompatibility complex molecules isolated from transfected Drosophila melanogaster cells
53. Distinct conformations of a peptide bound to HLA-DR1 or DRB5*0101 suggested by molecular modeling
54. Ligands motifs of HLA-DRB5*0101 and DRB1*1501 molecules delineated form self-peptides
55. Single step method of RNA isolation by acid guanidium-isothiocyanate-phenol-chloroform extraction
56. Studies on the human T cell receptor α/β variable region genes
57. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles
58. Fine specificity of the myelin-reactive T cell repertoire; implications for TCR antagonism in autoimmunity
59. Anergic T cells as suppressor cells in vitro
60. Anergic T cells affect linked suppression
61. Altered hapten ligands antagonize trinitrophenyl-specific citotoxic T cells and block internalization of hapten-specific receptors
62. A T cell receptor (TCR) antagonist competitively inhibits serial TCR triggering by low-affinity ligands, but does not affect triggering by high-affinity anti-CD3 antibodies
63. Peptide-induced T cell receptor down-regulation on naive T cells predicts agonist properties and strictly correlates with T cell activation
64. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an infuenza virus peptide
65. Molecular mimicry in T cell-mediated autoimmunity: Viral peptides activate human T cell clones specific for myelin basic protein
66. The specificity and orientation of a TCR to its peptide-MHC class II ligands
67. Allopeptide-specific T cell reactivity altered by peptide analogs
68. Altered peptide ligand design: Altering immune responses to class I MHC/peptide complexes
69. Tickling the TCR: Selective T-cells functions stimulated by altered peptide ligand
70. Partial signaling by CD8+ T cells in response to antagonist ligands
71. Altered T cell receptor ligands trigger a subset of early T cell receptor
72. Dissociation of intracellular signaling pathways in response to partial agonist ligands of the T cell receptor
73. Peptides derived form self-proteins as partial agonists and antagonists of the human CD8+ T-cell clone reactive to melanoma/melanocyte epitope MART1(27-35)
74. An altered peptide ligand specifically inhibits Th2 cytokine synthesis by abrogating TCR signaling
75. Anergic T cells as suppressor cells in vitro and in vivo
76. Haplotype specific suppressor T cells, mediating linked suppression of immune responses elicited by third party H-2 alloantigens
77. Immunological unresponsiveness induced by recipient cells transfected with donor MHC genes
78. Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: Influence of MHC binding affinity
79. T cell suppression in transplantation tolerance through linked recognition
80. Cutting edge: Linked suppression of skin graft rejection can operate through indirect recognition